Global Bioinformatics Partnering Terms and Agreements 2014 to 2020
US$ 3,495.00
... companies. Trends in bioinformatics partnering deals Deal terms analysis Partnering agreement structure Partnering contract documents Top deals by value Most active deal makers Financial deal terms for bioinformatics The Global Bioinformatics Partnering Terms and Agreements 2014 ...
December 2020
650 pages
Global Gynecology Partnering 2010-2020: Deal trends, players and financials
US$ 3,495.00
... scope Global Gynecology Partnering 2014 to 2019 is intended to provide the reader with an in-depth understanding and access to Gynecology trends and structure of deals entered into by leading companies worldwide. Global Gynecology Partnering 2014 to 2019 ...
December 2020
300 pages
Global Genetic Disorders Partnering 2014-2020: Deal trends, players and financials
US$ 3,495.00
... access to Genetic Disorders trends and structure of deals entered into by leading companies worldwide. Global Genetic Disorders Partnering 2014 to 2019 includes: Trends in Genetic Disorders dealmaking in the biopharma industry since 2014 Analysis of Genetic Disorders deal structure ...
December 2020
350 pages
Global Hospital Care Partnering 2014-2020: Deal trends, players and financials
US$ 3,495.00
... access to Hospital Care trends and structure of deals entered into by leading companies worldwide. Global Hospital Care Partnering 2014 to 2019 includes: Trends in Hospital Care dealmaking in the biopharma industry since 2014 Analysis of Hospital Care deal structure ...
December 2020
600 pages
Global Regenerative Medicine Partnering Terms and Agreements 2014 to 2020
US$ 3,495.00
... access to the regenerative medicine including cell therapy, organ regeneration, stem cells and tissue regeneration partnering deals and agreements entered into by the worlds leading healthcare companies. DESCRIPTION The Global Regenerative Medicine Partnering 2014-2019: Deal trends, players ...
December 2020
850 pages
Global Monoclonal Antibody Partnering Terms and Agreements 2014 to 2020
US$ 3,495.00
... Access to over 640 monoclonal antibodies deal records The leading monoclonal antibodies deals by value since 2014 Includes chimeric mAb, humanized mAb, human mAb and murine mAb deals and alliances since 2014 In Global Monoclonal antibody Partnering Terms and Agreements 2014 to 2098 ...
December 2020
500 pages
Global Diagnostic Imaging Partnering Terms and Agreements 2014 to 2020
US$ 3,495.00
... imaging partnering deals. This report provides details of the latest diagnostics agreements announced in the healthcare sectors, covering: Imaging CT Endoscope Molecular and nuclear PET SPECT MRI Ultrasound X ray Angiography Fluoroscopy Mammography This report provides an overview of diagnostic imaging ...
December 2020
350 pages
Global Gene Therapy Partnering Terms and Agreements 2010 to 2020
US$ 3,495.00
... -life gene therapy deals Access to over 220 gene therapy deals The leading gene therapy deals by value since 2014 Most active gene therapy dealmakers since 2014 The leading gene therapy partnering resources In Global Gene Therapy Partnering Terms and ...
December 2020
400 pages
Global Genomics Partnering Terms and Agreements 2014 to 2020
US$ 3,495.00
... , upfronts, milestones and royalties by stage of development Genomics partnering contract documents Top Genomics deals by value The Global Genomics Partnering Terms and Agreements report provides an understanding and ...
December 2020
550 pages
Global Microbiome Partnering Terms and Agreements 2010 to 2020
US$ 3,495.00
... , upfronts, milestones and royalties by stage of development Microbiome partnering contract documents Top Microbiome deals by value The Global Microbiome Partnering Terms and Agreements report provides an understanding and ...
December 2020
150 pages
Global Proteomics Partnering Terms and Agreements 2010 to 2020
US$ 3,495.00
... , upfronts, milestones and royalties by stage of development Proteomics partnering contract documents Top Proteomics deals by value The Global Proteomics Partnering Terms and Agreements report provides an understanding and ...
December 2020
400 pages
Global Companion Diagnostics Partnering Terms and Agreements 2010-2020
US$ 3,495.00
... Case studies of real-life Companion Diagnostics deals Access to Companion Diagnostics contract documents Leading Companion Diagnostics deals by value since 2014 Most active Companion Diagnostics dealmakers since 2014 In Global Companion Diagnostics Partnering 2014-2019: Deal trends, players, financials and ...
November 2020
300 pages
Global Cancer Vaccine Partnering Terms and Agreements 2010-2020
US$ 3,495.00
... Case studies of real-life Cancer Vaccine deals Access to Cancer Vaccine contract documents Leading Cancer Vaccine deals by value since 2014 Most active Cancer Vaccine dealmakers since 2014 In Global Cancer Vaccine Partnering 2014-2019: Deal trends, players, financials and ...
November 2020
250 pages
Global Antibody Partnering Terms and Agreements 2014-2020
US$ 3,495.00
... announced in the healthcare sectors, covering: Antibodies Antibody-drug conjugates Monoclonal antibodies Murine mAb Chimeric mAb Humanized mAb Human aAb Polyclonal Antibodies Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process ...
November 2020
950 pages
Global Oncology Partnering 2015-2020: Deal trends, players and financials
US$ 3,495.00
... , Vomiting, Chemotherapy, Radiotherapy, Adenocarcinoma, Basal cell carcinoma, Bile duct cancer, Bladder cancer, Bone cancer, Brain cancer, Breast cancer, Cervical cancer, Colorectal cancer, Endometrial, Esophageal cancer, Gastric cancer, Head and neck cancer, Kaposi's sarcoma, Kidney cancer, Leukemia, Acute ...
November 2020
2600 pages
Global Antibiotics Partnering Terms and Agreements 2010 to 2020
US$ 3,495.00
... healthcare sectors, covering: Antibiotics Aminoglycosides Cephalosporin Clindamycin Macrolides Penicillin Quinolones Sulfonamides Tetracycline Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into ...
November 2020
250 pages
Global Cancer Diagnostics Partnering Terms and Agreements 2014-2020
US$ 3,495.00
... Case studies of real-life Cancer Diagnostics deals Access to Cancer Diagnostics contract documents Leading Cancer Diagnostics deals by value since 2014 Most active Cancer Diagnostics dealmakers since 2014 In Global Cancer Diagnostics Partnering 2014-2019: Deal trends, players, financials and ...
November 2020
500 pages
Global Orphan Diseases Partnering 2010-2020: Deal trends, players and financials
US$ 3,495.00
... to hundreds of Orphan Diseases deal contract documents Comprehensive access to over 120 Orphan Diseases deal records The leading Orphan Diseases deals by value since 2014 Most active Orphan Diseases dealmakers since 2014 In Global Orphan Diseases Partnering 2014 to 2019, available deals and ...
November 2020
200 pages
Global Diagnostics Partnering Terms and Agreements 2014-2020
US$ 3,495.00
... healthcare sectors, covering: Companion Diagnostics Imaging CT Endoscope Molecular and nuclear MRI Ultrasound X-ray PET SPECT Angiography Fluroscopy Mammography In vitro diagnostics Molecular diagnostics Prognostics Theranostics The report provides a detailed ...
November 2020
1450 pages
Global Drug Delivery Partnering Terms and Agreements 2014-2020
US$ 3,495.00
... Drug Delivery deals Access to Drug Delivery contract documents Leading Drug Delivery deals by value since 2014 Most active Drug Delivery dealmakers since 2014 In Global Drug Delivery Partnering 2014-2019: Deal ... at signing Deal component type Specific therapy target Technology type Each deal title links ...
November 2020
750 pages
Global In Vitro Diagnostics Partnering Terms and Agreements 2014-2020
US$ 3,495.00
... of real-life In Vitro Diagnostics deals Access to In Vitro Diagnostics contract documents Leading In Vitro Diagnostics deals by value since 2014 Most active In Vitro Diagnostics dealmakers since 2014 In Global In Vitro Diagnostics Partnering 2014-2019: Deal trends, players ...
November 2020
350 pages
Global Stem Cell Partnering Terms and Agreements 2010-2020
US$ 3,495.00
... Case studies of real-life Stem Cell deals Access to Stem Cell contract documents Leading Stem Cell deals by value since 2014 Most active Stem Cell dealmakers since 2014 In Global Stem Cell Partnering 2014-2019: Deal trends, players, financials and ...
November 2020
450 pages
Global Precision Medicine Partnering Terms and Agreements 2014-2020
US$ 3,495.00
... unprecedented access to the personalized medicine partnering deals and agreements entered into by the worlds leading healthcare companies DESCRIPTION The Global Precision Medicine Partnering 2014-2019 report provides comprehensive understanding ...
November 2020
700 pages
Global Cardiovascular Partnering 2014-2020: Deal trends, players and financials
US$ 3,495.00
... heart failure, Coronary artery disease, Ductus arteriosus, Fatigue, Hypercholesterolemia, Hypertension, Intermittent claudication, Ischemic heart disease, Limb ischemia, Marfan's Syndrome, Myocardial Infarction, Oedema (excess fluid), Palpitations, Peripheral arterial disease, Thrombus (blood clot), Valvular ...
October 2020
500 pages
Global Central Nervous System Partnering 2014-2020: Deal trends, players and financials
US$ 3,495.00
... Cerebral palsy, Creutzfeldt Jakob disease, Dizziness, Epilepsy, Faints, Falls, Guillain Barre syndrome, Headache, Meningitis (Bacterial, Meningococcal, Pneumococcal), Mycobacterium tuberculosis (TB), Haemophilus influenzae Type B (Hib), Migraine, Motor Neurone Disease (Amyotrophic Lateral Sclerosis/Lou Gehrig ...
October 2020
950 pages
Global Dental Partnering 2010-2020: Deal trends, players and financials
US$ 3,495.00
... DESCRIPTION Global Dental Partnering 2014 to 2019 provides the full collection of Dental disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014. Trends in Dental partnering deals Financial deal terms ...
October 2020
200 pages
Global Gastrointestinal Partnering 2014-2020: Deal trends, players and financials
US$ 3,495.00
... , Esophagitis, Gastritis, Gastroenteritis, Hemorrhoids (haemorrhoids), Hernia, Inflammatory bowel disease, Crohn's disease, Ulcerative colitis, Irritable bowel syndrome, Malabsorption, Malnutrition, Pancreatitis, Peptic ulce, Gastric ulcer, Duodenal ulcer, Abdominal pain, Ascites, Bowel movement, Constipation ...
October 2020
300 pages
Global Dermatology Partnering 2014-2020: Deal trends, players and financials
US$ 3,495.00
... deals for the following indications: Acne, Actinic keratosis, Angioedema, Burns, Cellulitis, Cosmetics, Dermatitis, Diabetic foot ulcer, Eczema, Hair disorders, Alopecia, Impetigo, Itching, Nail disorders, Psoriasis, Rosacea, Scabies, Sun damage, Rash, Scar, Venous ulcer, Verruca, Wound healing, Wrinkles ...
October 2020
400 pages
Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014 to 2020
US$ 3,495.00
... including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche ...
October 2020
450 pages
Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2014-2020
US$ 3,495.00
... including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche ...
October 2020
2800 pages
Global Licensing Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2014-2020
US$ 3,495.00
... latest licensing agreements announced in the pharmaceutical, biotechnology ... licensing deals by value since 2014 Most active licensing dealmakers since 2014 The leading licensing partnering resources In Global Licensing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014- 2019 available deals ...
October 2020
2400 pages
Global Option and Evaluation Partnership Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2020
US$ 3,495.00
... including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche ...
October 2020
850 pages